Insider Trading Disclosure
Nureca Reports Promoter Group Share Purchase
Nureca disclosed that promoter group member Smita Goyal purchased 1,155 equity shares worth Rs 3.49 lakh on 11 November 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
7
Bullish
4
Bearish
33
Neutral
7
Bullish
6
Bearish
30
Neutral
0
Bullish
2
Bearish
30
Neutral
0
Bullish
2
Bearish
30
Neutral
0
Bullish
2
Bearish
30
Neutral
0
Bullish
2
Healthcare Equipment & Supplies
Medical Equipment & Supplies
284 Cr
Moderate Risk
59.7
60.5
0.4
1.5
375.00
200.10
Sales CAGR
Profit CAGR
ROE
ROCE
Nureca Ltd (NURECA) is currently trading at 301.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Nureca Limited is a digitally native consumer healthcare company that designs, manufactures and sells home diagnostics, wellness devices and personal fitness equipment under owned brands such as Dr. Trust, Dr. Physio and Trumom across D2C and marketplace channels. Financial performance has strengthened year-on-half-year: consolidated revenue for the half year ended September 30, 2026 rose to Rs. 1,918.69 million versus Rs. 1,419.16 million a year earlier, with consolidated profit after tax improving to Rs. 71.18 million, signalling accelerating scale despite seasonal and working capital swings. Balance sheet and working capital dynamics are changing materially: inventories and trade receivables are substantially higher while bank deposits expanded to Rs. 694.49 million, reflecting both inventory build-up for scale and temporary cash placement decisions by Nureca Limited to manage liquidity and capex. Operating cash flow turned negative for the half year due to sizeable working capital absorption while the company simultaneously recorded large investing spend on property, plant and equipment and capital work-in-progress; this indicates a near-term cash conversion strain as Nureca Limited invests to expand manufacturing and fulfil omnichannel growth.
Over the past 52 weeks, Nureca Ltd has traded between a low of ₹200.10 and a high of ₹375.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Nureca Ltd has a market capitalization of approximately 284.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Nureca Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 59.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 284.35 Cr, Nureca Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Nureca Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Nureca Ltd is 59.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Nureca reported consolidated revenue from operations of ₹58.53 crore for Q2 FY27 (quarter ended 30 September 2026), about 55% higher than the year-ago quarter.
Saurabh Goyal acquired 32,19,113 shares off-market, increasing his holding to 64,97,169 shares or 68.09% voting rights, while Payal and Aryan Goyal moved to zero shareholding.
